- Novartis will spend $250 million to research and develop new treatments for neglected tropical diseases over the next five years, announcing the investment on Wednesday alongside an international meeting.
- The spending is part of Novartis’ endorsement of the Kigali Declaration, a commitment to end neglected tropical diseases that is being announced at a summit in Kigali, Rwanda. The declaration focuses on securing resources to combat diseases like Dengue fever, Chagas disease and leishmaniasis, which predominantly affect people in countries near the equator, particularly those in impoverished communities.
- Unlike other, more common infectious diseases like HIV, tuberculosis or malaria, neglected tropical diseases receive less attention and garner fewer research dollars. Still, a few big pharmaceutical companies like Novartis, Pfizer and GSK do invest in R&D — GSK, for instance, announced Thursday plans to invest $1 billion euros into infectious disease research over the next 10 years.